The American multinational recently announced that it would partner with BADRA (Biomedical Advanced Research and Development Authority) to find antiviral vaccines for COVID-19. By funding a generous $1 billion to the research, Johnson & Johnson hopes to have clinical trials by September of this year and that the vaccine would be commercially available for public use by early 2021. The company also promises that it would make the medicine affordable and available to every country that has been affected by the pandemic on a non-profit basis.
#JNJ announces a lead #COVID19 vaccine candidate plus a landmark partnership with @BARDA to together commit over $1 billion of investment to co-fund vaccine research, development & clinical testing & a commitment by J&J to accelerated manufacturing plans: https://t.co/kTMcJ63tBDpic.twitter.com/WuOcS198om
— Johnson & Johnson (@JNJNews) March 30, 2020
Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020
Johnson & Johnson Will Establish New U.S. Vaccine Manufacturing Capabilities and Additional Production Capacity Outside the U.S. to Begin Production at Risk to Help Ensure Global Vaccine Supply
To date, there have been 786,973 positive cases of Corona worldwide. Several billionaires, pharmaceutical companies, and scientists are working day and night to find a vaccine that could eradicate the virus.